Equities

X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.6175
  • Today's Change0.001 / 0.13%
  • Shares traded1.01m
  • 1 Year change-16.61%
  • Beta0.4628
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments11412282
Total Receivables, Net0.561.150.75
Total Inventory------
Prepaid expenses7.055.525.34
Other current assets, total0.250.290
Total current assets12212988
Property, plant & equipment, net6.408.3310
Goodwill, net171717
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.650.200.40
Total assets147156117
LIABILITIES
Accounts payable8.957.784.28
Accrued expenses14138.95
Notes payable/short-term debt000
Current portion long-term debt/capital leases01.320.80
Other current liabilities, total------
Total current liabilities232214
Total long term debt553233
Total debt553434
Deferred income tax------
Minority interest------
Other liabilities, total19275.60
Total liabilities968253
SHAREHOLDERS EQUITY
Common stock0.170.120.03
Additional paid-in capital529451347
Retained earnings (accumulated deficit)(478)(377)(283)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.12)(0.12)(0.12)
Total equity517464
Total liabilities & shareholders' equity147156117
Total common shares outstanding16712228
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.